Precipio, Inc. has demonstrated robust top-line growth, with fiscal year 2025 revenue increasing 30% year-over-year to $24.0 million, driven by expansion in its Pathology Services division and growing adoption of its proprietary HemeScreen and Bloodhound molecular platforms. The company achieved positive operating cash flow and positive adjusted EBITDA in Q4-2025, signaling a potential path toward financial independence. However, Q1-2026 results highlighted near-term profitability headwinds, including a negative adjusted EBITDA of $(0.16) million due to CMS reimbursement cuts, strategic commercial investments, and temporary product shipment delays. Furthermore, the company's auditors continue to express substantial doubt about its ability to continue as a going concern due to an accumulated deficit of $102.8 million and limited cash reserves of $2.6 million as of year-end 2025. While the underlying business fundamentals and commercial pipeline remain strong, a 'Hold' recommendation is warranted until the company demonstrates sustainable profitability and resolves its going-concern uncertainties.